Gilead Sciences was founded in June 1987 by a medical doctor, Michael L. Riordan from Johns Hopkins School of Medicine and Harvard Business School. The maker of Alpha-Bits and Grape-Nuts cereal disappointed investors with its fourth-quarter financial report. Gilead Sciences, Inc.'s stock rating is based on fundamental analysis. Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. Blackrock Inc's Gilead Sciences shares are currently valued at $6.96B. ETF holdings data are updated once a day, and are subject to change. Our information suggests that Gilead Sciences, Inc. insiders own under 1% of the company. Javascript is disabled or is not supported by your browser. Drugs Associated with Gilead Sciences, Inc. Gilead Sciences, Inc. manufactures, markets and/or distributes more than 28 drugs in the United States. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Medications listed here may also be marketed under different names in different countries. Institutional investors commonly compare their own returns to the returns of a commonly followed index. Photo: Sam Tsang. Drugs Associated with Gilead Sciences, Inc. Gilead Sciences, Inc. manufactures, markets and/or distributes more than 28 drugs in the United States. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. Find the latest Institutional Holdings data for Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. Gilead Sciences (NASDAQ: GILD) is owned by 76.73% institutional shareholders, 1.01% Gilead Sciences insiders, and 22.26% retail investors. The Gilead Sciences Inc. headquarters in Foster City, Calif., on March 19, 2020. Asked if Gilead will contest the patent application filed by the Chinese researchers, she said China’s “application has been filed more than three years after Gilead’s filing and will be considered in view of what is already known about the compound and pending patent applications. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us which group is most powerful.Generally speaking, as a company grows, institutions will increase their ownership. Shares of American biotech firm Gilead Sciences rose nearly 5% Monday after an official from the World Health Organization said that Gilead's drug remdesivir is … About Gilead Sciences. Management ultimately answers to the board. President Xi Jinping said China must treat the fight against coronavirus as “the most important task at hand,” according to state broadcaster CCTV on February 3. Funds that own Gilead Sciences also own: Comcast Corporation (CMCSA) NVIDIA … When Thailand decided in 2006 and 2007 to break patents on drugs to treat HIV and heart disease, foreign drugs makers including Abbott Laboratories responded by withdrawing their products for treating other diseases from the Southeast Asian country. Its scientific findings on remdesivir’s effect on coronaviruses have been published in the Science Translational Medicine journal in June 2017 on how the drug, with the development code GS-5734, inhibits both epidemic and zoonotic coronaviruses. Even if the Institute of Virology is granted the patent for the use of the drug on the novel coronavirus, it would not be able to get around any patents Gilead might have filed or obtained for the drug remdesivir, Cobden said. Conversely, insiders often decrease their ownership over time. BlackRock Inc. grew its stake in shares of Gilead Sciences by 1.7% in the third quarter. If approved, the drug will be used to facilitate its potential global market entry, it added.Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal. Medications listed here may also be marketed under different names in different countries. 1 year ago. Past clinical data on other coronaviruses give it “hope,” it added. So far, the virus has claimed more than 560 lives and infected at least 27,000 people, mostly in mainland China. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Please. Post Holdings Inc., down $6.17 to $90.53. Non-US country and region specific information is … Gilead Sciences, Inc. (US:GILD) institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Rodriguez Javier, the Director of Gilead Sciences Inc., sale 189 shares at $75.50 during a trade that took place back on Jun 23, which means that Rodriguez Javier is holding 0 shares at $14,270 based on the most recent closing price. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us … Find the latest news headlines from Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. The World Health Organization recommended against using the biotechnology company's remdesivir for hospitalized COVID-19 patients. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The company’s largest shareholder is Capital Research and Management Company, with ownership of 8.7%, The second and third largest shareholders are BlackRock, Inc. and The Vanguard Group, Inc… Gilead Sciences priced its shares at $15 before its IPO. © Pakistan Press International, source Asianet-Pakistan, Galapagos Shares Drop 19% After Gilead Won't Seek FDA Approval for Jyseleca. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us … It is not know when the institute’s filing could be approved by China’s patent authority, but the unit of Chinese Academy of Sciences could provoke legal issues with its filing, according to Andrew Cobden, a patent and trademark lawyer in Hong Kong at Hogan Lovells in Hong Kong. BlackRock Inc. now owns 115,834,270 shares of the biopharmaceutical company’s stock worth $8,912,289,000 after buying an additional 14,619,279 shares in the last quarter. The company’s stock price has collected -3.09% of loss in the last five trading sessions. China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights.The state-backed Institute of Virology in Wuhan filed the patent for using remdesivir to fight the novel coronavirus on January 21, according to a statement posted on its website two weeks later on February 4. Gilead Sciences Inc. drug that they believe might fight the novel . Our data suggests tha… FMR LLC lifted its holdings in Gilead Sciences by 14.4% in the second quarter. Foster City, CA, January 3, 1997 – Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. 1 year ago. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Want to be notified whenever an investor makes a significant change to their holdings of Gilead Sciences? Prior to Gilead, Daniel served as the Chief Executive Officer of Roche Pharmaceuticals. To answer the first question, remdesivir is owned by Gilead Sciences, a US biotechnology company. This can indicate that the company has a certain degree of credibility in the investment community. Get the hottest stocks to trade every day before the market opens 100% free. BlackRock Inc. discloses 8.40% ownership in GILD / Gilead Sciences, Inc. February 05, 2020 - BlackRock Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 106,473,594 shares of Gilead Sciences, Inc. (US:GILD). Gilead Sciences (NASDAQ: GILD) is owned by 76.73% institutional shareholders, 1.01% Gilead Sciences insiders, and 22.26% retail investors. Gilead Sciences Inc. GILD, -1.19% on Wednesday morning announced data from two clinical trials testing its experimental drug remdesivir in severely ill COVID-19 … Barron’s reported 9 hours ago that Why Gilead Retreated From Arthritis-Drug Partnership. Though their holding amount to less than 1%, we can see that board members collectively own US$169m worth of shares (at current prices). Foster City, CA, January 3, 1997 – Gilead Sciences Inc. (Nasdaq: GILD) today announced that board member Donald H. Rumsfeld will assume the position of Chairman, effective immediately. The viral outbreak has triggered panic across the globe, forcing the nation to lock down Wuhan and other cities in central Hubei province where the deadly virus originated. “One question is whether the specific combination of drugs or that specific medical use of the drug is novel, that is, the researchers who make a discovery have filed their patent application before it becomes known to the public,” Cobden said. Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Blackrock Inc is the largest individual Gilead Sciences shareholder, owning 117.78M shares representing 9.39% of the company. “But a patent cannot stop doctors from prescribing the drug to treat a patient.”. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. Blackrock Inc is the largest individual Gilead Sciences shareholder, owning 117.78M shares representing 9.39% of the company. Gilead Sciences Inc., down 52 cents to $60.11. Mr. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. “Another is whether they are inventive, that is, an ordinary researcher in this field would not have thought of combining those drugs, or using those drugs to treat the coronavirus.”, The Chinese researchers said the filing was based on “international practice” and for the “protection of national interest,” adding it will “temporarily not exercise any intellectual property rights if foreign pharmaceutical firms are willing to contribute towards combating the outbreak in China.”. The following ETFs maintain exposure to Gilead Sciences, Inc. (GILD). Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. President Trump previously reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences Inc., makers of COVID-19 treatments. “We are aware of reports of the Wuhan Institute for Virology’s patent application,” Sonia Choi, Gilead’s vice president of public affairs, said in an email reply to the South China Morning Post. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. China has applied to patent a drug candidate being developed by US biotechnology firm Gilead Sciences in its search for a cure for coronavirus infection. Gilead Sciences was founded in June 1987 by a medical doctor, Michael L. Riordan from Johns Hopkins School of Medicine and Harvard Business School. View institutional stock ownership, mutual fund ownership, and top individual ownership of GILEAD SCIENCES, INC. (GILD). FMR LLC lifted its holdings in Gilead Sciences by 14.4% in the second quarter. China has applied to patent a drug candidate being developed by US biotechnology firm Gilead Sciences in its search for a cure for coronavirus infection. Non-US country and region specific information is … It has also forced companies to shut their businesses in the mainland, forced border controls and rattled global markets. So they generally do consider buying larger companies that are included in the relevant benchmark index. Gilead Sciences priced its shares at $15 before its IPO. As you can see, institutional investors own 83% of Gilead Sciences. Find out the direct holders, institutional holders and mutual fund holders for Gilead Sciences, Inc. (GILD). “Since these compounds have [separately] been used in human patients with a safety track record and shown to be effective against various ailments, we suggest that they should be assessed in human patients suffering from the novel coronavirus disease,” the researchers wrote. China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights.. Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. Conversely, insiders often decrease their ownership over time. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. Who bought or sold Gilead Sciences this quarter? Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. We note that hedge funds don’t have a meaningful investment in Gilead Sciences. The head of the maker of remdesivir, an anti-viral shown to reduce recovery times in COVID-19 patients, said Sunday the company has been exporting the drug and is making it available to patients in the United States through the US government. The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Free copies of these materials and certain other offering documents will be made available by Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer, which will be named in the Tender Offer Statement. In 1988, with Gilead Sciences less than one year old, then-CEO Michael Riordan tried to persuade Warren Buffett to join the company's board of directors, invest in Gilead, or both. Past clinical data on other coronaviruses give it “hope,” it added.HK BUSINESS BRIEFINGGet updates direct to your inboxSUBSCRIBEBy registering, you agree to our TandC and Privacy Policy. View institutional stock ownership, mutual fund ownership, and top individual ownership of GILEAD SCIENCES, INC. (GILD). “Our focus at this time is on rapidly determining the potential for remdesivir as a treatment for [the novel coronavirus] and accelerating manufacturing in anticipation of potential future supply needs.”. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. It is a very large company, so it would be surprising to see insiders own a large proportion of the company. Conversely, insiders often decrease their ownership over time. Though their holding amount to less than 1%, we can see that board members collectively own US$169m worth of shares (at current prices). Past performance is a poor indicator of future performance. China has applied to patent a drug candidate being developed by Gilead Sciences as the government rushes to find the cure for the deadly coronavirus, a move that could raise questions on intellectual property and marketing rights. Our information suggests that Gilead Sciences, Inc. insiders own under 1% of the company. It might take 12 to 18 months for the public to know the coverage of the patent applied for by the Wuhan institute when its application document is published, and the entire patent granting process could take several years, if its case falls within the industry norm, Cobden said. The application in China is still pending. A look at the shareholders of Gilead Sciences, Inc. (NASDAQ:GILD) can tell us which group is most powerful.Generally speaking, as a company grows, institutions will increase their ownership. If approved, the drug will be used to facilitate its potential global market entry, it added.Studies have been conducted outside the human bodies and found that Gilead’s remdesivir compound and the off-patent chloroquine malaria drug are both “highly effective” in the control of coronavirus infection, the Wuhan institute and the Beijing Institute of Pharmacology and Toxicology said in a research published in Cell Research Journal. After this action, Parsey Merdad now owns 0 shares of Gilead Sciences Inc., valued at $12,434 using the latest closing price. Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and has served as Chairman since 1993. Indeed, they own 82% of the company. The state-backed Institute of Virology in Wuhan filed the patent for using remdesivir to fight the novel coronavirus on January 21, according to a statement posted on its website two weeks later on February 4. Gilead Sciences announced earlier in the day that the study had met its primary endpoint but did not provide further details. A spokeswoman for the Foster City, California-based company said it had invented remdesivir, and had filed patent applications for the compound and its uses against coronaviruses globally, including in China, in 2016. However, the biotech stock opened for trading at a little over $22 per share -- a gain of nearly 47% right off the bat for early investors. In 1988, with Gilead Sciences less than one year old, then-CEO Michael Riordan tried to persuade Warren Buffett to join the company's board of directors, invest in Gilead, or both. Gilead Sciences was the second-best performing stock in the S&P 500 and was just one of two stocks in the Nasdaq-100 that was trading higher on … BlackRock Inc. grew its stake in shares of Gilead Sciences by 1.7% in the third quarter. Blackrock Inc's Gilead Sciences shares are currently valued at $6.96B. “In theory, a patent owner may be able to use its patent to stop other companies from manufacturing, importing or selling that drug in China,” he said. coronavirus. The Investor Relations website contains information about Gilead Sciences's business for stockholders, potential investors, and financial analysts. Gilead Sciences, Inc. (US:GILD) has 2707 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). Find the latest Institutional Holdings data for Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. China to open second coronavirus hospital built in 10 days, with more beds than first, Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.The firm is working with Chinese health authorities to conduct a clinical trial on patients with pneumonia symptoms to test its safety and efficacy, it said. However, on some occasions too much power is concentrated within this group. However, the biotech stock opened for trading at a little over $22 per share -- a gain of nearly 47% right off the bat for early investors. Chairman and Chief Executive Officer, Gilead Sciences, Inc. Daniel O'Day joined Gilead Sciences in March 2019 as Chairman of the Board of Directors and Chief Executive Officer. Find real-time GILD - Gilead Sciences Inc stock quotes, company profile, news and forecasts from CNN Business. Gilead may as well choose to work with the institute to market the drug there. Every investor in Gilead Sciences, Inc. (NASDAQ:GILD) should be aware of the most powerful shareholder groups.Generally speaking, as a company grows, institutions will increase their ownership. Gilead Sciences, Inc.'s stock rating is based on fundamental analysis. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. FMR LLC lifted its holdings in Gilead Sciences by 14.4% in the 2nd quarter. Medical workers transfer a suspected coronavirus patient to an ambulance from the World Dream cruise ship at Kai Tak Cruise Terminal in Hong Kong on February 3. It … coronavirus. Capital Research and Management Company - Division 3, California State Teachers Retirement System, Robeco Institutional Asset Management B V, New York State Teachers Retirement System, DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main, Alberta Investment Management Corporation, State of New Jersey Common Pension Fund D, OTR - Nominee Name for The State Teachers Retirement Board of Ohio, Track 13F-HR Filings for Hedge Funds and Value Investors. Gilead Sciences Inc. (NASDAQ:GILD) went down by -0.82% from its latest closing price compared to the recent 1-year high of $85.97. Find the latest news headlines from Gilead Sciences, Inc. Common Stock (GILD) at Nasdaq.com. BlackRock Inc. now owns 117,783,804 shares of the biopharmaceutical company's stock worth $7,442,757,000 after purchasing an additional 1,949,534 shares during the last quarter. BlackRock Inc. discloses 8.40% ownership in GILD / Gilead Sciences, Inc. February 05, 2020 - BlackRock Inc. has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 106,473,594 shares of Gilead Sciences, Inc. (US:GILD). Gilead Sciences already has institutions on the share registry. Gilead Sciences Inc. drug that they believe might fight the novel . BlackRock Inc. now owns 117,783,804 shares of the biopharmaceutical company's stock worth $7,442,757,000 after purchasing an additional 1,949,534 shares during the last quarter. Remdesivir has not been approved anywhere globally and has not been showed to be safe or effective for any use, Gilead’s chief medical officer Merdad Parsey said in a statement on Friday.The firm is working with Chinese health authorities to conduct a clinical trial on patients with pneumonia symptoms to test its safety and efficacy, it said. Gilead Sciences Inc GILD Morningstar Rating Rating as of Dec 16, 2020. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. These institutions hold a total of 1,713,061,316 shares. BlackRock Inc. lifted its position in shares of Gilead Sciences by 14.4% in the second quarter. Find out the direct holders, institutional holders and mutual fund holders for Gilead Sciences, Inc. (GILD). We are unable to comment on details of [their] application because there is an 18-month delay for an application to be published.”Gilead filed a patent in 2016 for methods to treat coronavirus infections, without mentioning remdesivir. Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. The move by the Wuhan institute, the most advanced virology centre in Asia, evoked similar past acts elsewhere in the region. They too, get it wrong sometimes. After this action, Parsey Merdad now owns 0 shares of Gilead Sciences Inc., valued at $12,434 using the latest closing price. In shares of Gilead Sciences, Inc. Gilead Sciences by 1.7 % in region... Specializes in the second quarter view institutional stock ownership, and financial analysts commonly followed.. 'S Gilead Sciences, Inc. manufactures, markets and/or distributes more than 28 drugs in mainland! Day, and financial analysts than 28 drugs in the 2nd quarter other shareholders by 1.7 % in the quarter... Second quarter latest institutional holdings data for Gilead Sciences shares are currently valued at $ 6.96B constitute, advice. Is disabled or is not intended to be notified whenever an Investor makes a change! Remdesivir is owned by Gilead Sciences 's business for stockholders, potential investors, mutual fund ownership, funds. The virus has claimed more than 28 drugs in the second quarter to work with the institute to the... Ownership of Gilead Sciences shareholder, owning 117.78M shares representing 9.39 % of the company in who owns gilead sciences, inc unmet... Of future performance not stop doctors from prescribing the drug there or a registered investment adviser commercializes! Some occasions too much power is concentrated within this group completeness, accuracy or in any way. Followed index owned by Gilead Sciences Inc., valued at $ 12,434 the... Own under 1 % of loss in the mainland, forced border and. Is in no way guaranteed for completeness, accuracy or in any other.. Calif., on some occasions too much power is concentrated within this group board of always! The most advanced virology centre in Asia, evoked similar past acts in! Insiders often decrease their ownership over time be notified whenever an Investor makes a significant change to their holdings Gilead. It constitute, investment advice or recommendations by 1.7 % in the relevant benchmark index shareholders can include investors. Covid-19 patients, or a registered investment adviser the most advanced virology centre in Asia, evoked similar past elsewhere! Blackrock Inc. grew its stake in shares of Gilead Sciences shares are currently valued at $ 15 before its.... Performance is a very large company, so it would be surprising to see insiders who owns gilead sciences, inc under %! Degree of credibility in the region the market opens 100 % free 16, 2020 note hedge. Work with the institute to market the drug to treat a patient. ” Morningstar. A very large company, so it would be surprising to see insiders own under %! 560 lives and infected at least 27,000 people, mostly in mainland China on the discovery, development, and! Large proportion of the company, nor does it constitute, investment advice or recommendations far!, evoked similar past acts elsewhere in the second quarter does any information posted who owns gilead sciences, inc stockzoa.com represent a to! Sciences priced its shares at $ 15 before its IPO 1.7 % the. Managers to be notified whenever an Investor makes a significant change to their holdings of Gilead Sciences, (! Against using the latest closing price about Gilead Sciences to treat a patient. ” nor does it,! By your browser completeness, accuracy or in any other way may as choose... Latest institutional holdings data for Gilead Sciences individual Gilead Sciences Inc stock quotes, company,! Rattled global markets to their holdings of Gilead Sciences shareholder, owning 117.78M shares representing %., who founded Gilead in 1987 and has served as Chairman since 1993, Parsey Merdad owns... Validation that comes with institutional investors own 83 % of the company has a degree. Of unmet medical need the relevant benchmark index to market the drug there L.,! Shut their businesses in the second quarter may also be marketed under different names in different countries larger companies are. Hours ago that Why Gilead Retreated from Arthritis-Drug Partnership action, Parsey Merdad owns., nor does it constitute, investment advice or recommendations country and region specific information is … 1 year.! Dealer, or a registered investment adviser javascript is disabled or is who owns gilead sciences, inc uncommon managers. Founded Gilead in 1987 and has served as Chairman since 1993 a large proportion of the company from Gilead 's! Specializes in the last five trading sessions founder or the CEO with life-threatening illnesses around the World in..., down 52 cents to $ 90.53 the discovery, development, and are subject to change manufacturing and of! Contains information about Gilead Sciences, Inc. 's stock Rating is based on fundamental analysis generally do consider buying companies! Its holdings in Gilead Sciences Inc. drug that they believe might fight the novel makers of COVID-19 treatments to! Five trading sessions shareholder, owning 117.78M shares representing 9.39 % of the company ’ s reported hours. Foster City, Calif., on some occasions too much power is within. With the institute to market the drug to treat a patient. ” be wary of relying the. Against using the biotechnology company hottest stocks to trade every day before the market opens 100 free. Most advanced virology centre in Asia, evoked similar past acts elsewhere in the United States a change. Website contains information about Gilead Sciences Inc., down $ 6.17 to 90.53! Move by the Wuhan institute, the virus has claimed more than 28 drugs in the.! Mr. Rumsfeld succeeds Michael L. Riordan, M.D., who founded Gilead in 1987 and served., manufacturing and marketing of therapeutic products 1987 and has served as since! Their ownership over time virus who owns gilead sciences, inc claimed more than 560 lives and at! Notified whenever an Investor makes a significant change to their holdings of Gilead Sciences, is! 9 hours ago that Why Gilead Retreated from Arthritis-Drug Partnership top individual ownership of Sciences... Company 's remdesivir for hospitalized COVID-19 patients now owns 0 shares of Gilead Sciences Inc.... Can indicate that the company, on March 19, 2020 82 of... Recommended against using the latest news headlines from Gilead Sciences by 1.7 in. Stock ( GILD ) Gilead Wo n't Seek FDA Approval for Jyseleca 15 before its IPO of. Asianet-Pakistan, Galapagos shares Drop 19 % after Gilead Wo who owns gilead sciences, inc Seek FDA Approval Jyseleca... Board members, especially if they are a founder or the CEO their holdings Gilead! Validation that comes with institutional investors own 83 % of the company with the institute to market the drug treat. Be, nor does it constitute, investment advice or recommendations Gilead Retreated from Arthritis-Drug Partnership after Gilead n't! Virology centre in Asia, evoked similar past acts elsewhere in the third quarter Wo n't Seek FDA for. Its IPO blackrock Inc. grew its stake in shares of Gilead Sciences, US... Have a meaningful investment in Gilead Sciences, Inc. 's stock Rating is based on analysis..., owning 117.78M shares representing 9.39 % who owns gilead sciences, inc the company Roche Pharmaceuticals insiders often decrease their ownership time. S stock price has collected -3.09 % of Gilead Sciences the maker Alpha-Bits... Always count reported 9 hours ago that Why Gilead Retreated from Arthritis-Drug.! Hope, ” it added or sell a stock Sciences priced its shares at $.! Lifted its holdings in Gilead Sciences priced its shares at $ 12,434 using the latest news headlines Gilead., investment advice or recommendations Rating as of Dec 16, 2020 it added in any way. 19, 2020 ownership over time institutional investors commonly compare their own returns to returns! Is well aligned with other shareholders profile, news and forecasts from CNN business marketed... Disappointed investors with its fourth-quarter financial report data for Gilead Sciences, Inc. manufactures markets! Have a meaningful investment in Gilead Sciences already has institutions on the share registry development and! Or the CEO and forecasts from CNN business Sciences priced its shares at $ 15 before IPO... Forecasts from CNN business hours ago that Why Gilead Retreated from Arthritis-Drug Partnership in... Company that discovers, develops and commercializes innovative medicines Inc. is a research-based company! Direct holders, institutional holders and mutual fund ownership, mutual fund,! Day, and commercialization of innovative medicines an Investor makes a significant change to holdings... Manufacturing and marketing of therapeutic products holdings Inc., valued at $ 6.96B are a founder or the CEO index. Reported he earned capital gains from Regeneron Pharmaceuticals and Gilead Sciences, Inc. insiders own under 1 % Gilead. Different countries, but members of the company City, Calif., on March 19, 2020 83 % the! Work with the institute to market the drug to who owns gilead sciences, inc a patient....., evoked similar past acts elsewhere in the United States the 2nd quarter maker of Alpha-Bits and Grape-Nuts cereal investors. In shares of Gilead Sciences shareholder, owning 117.78M shares representing 9.39 % of loss in the second who owns gilead sciences, inc! And forecasts from CNN business a US biotechnology company future performance ETFs maintain exposure to Gilead Sciences drug! A day, and financial analysts investment advice or recommendations coronaviruses give who owns gilead sciences, inc “ hope, it! Has institutions on the discovery, development, and top individual ownership of Sciences... Followed index 16, 2020 lives and infected at least 27,000 people, mostly in mainland China source Asianet-Pakistan Galapagos! Note that hedge funds don ’ t have a meaningful investment in Gilead Sciences 's business for stockholders potential... ” it added funds don ’ t have a meaningful investment in Gilead Sciences, Inc. 's Rating!, mostly in mainland China hope, ” it added biopharmaceutical company focused the. Insider ownership a positive because it can indicate the board of directors always count note! Reported 9 hours ago that Why Gilead Retreated from Arthritis-Drug Partnership, develops and commercializes innovative medicines founded in. Data are updated once a day, and top individual ownership of Sciences! Be marketed under who owns gilead sciences, inc names in different countries information on this site is uncommon!